Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of switching to rilpivirine plus other antiretrovirals in virologically suppressed HIV-1 infected children
2018-004301-32Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilpivirine in Human immunodeficiency virus infection type 1, sponsored by Janssen Pharmaceutical. Primary endpoint: Rilpivirine AUC0-24h. Started Jun 2019; status: completed.
02
Drugs
rilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-004301-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004301-32.